A Phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study)

James Arseneau, John A. Blessing, Frederick Stehman, Ramon McGehee

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The Gynecologic Oncology Group conducted a Phase II trial of carboplatin in patients with measurable advanced squamous cell carcinoma of cervix. No prior therapy with cytotoxic drugs was permitted in patients entered into this study. Patients entered were GOG performance status 2 or better. Carboplatin 400 mg/m2 (340 mg/m2 in patients who had had prior pelvic radiotherapy with subsequent escalation to 400 mg/m2 if bone marrow tolerance was good) was administered as a 15-minute IV infusion. Treatments were repeated every four weeks until disease progressed or until toxicity prohibited further therapy. Thirty-nine evaluable patients were treated. Two complete and nine partial responses were observed (response rate 28.2%). No neurotoxicity and only mild reversible nephrotoxicity was seen. Gastrointestinal toxicity was severe in three patients (7.7%). Dose limiting toxicity was myelosuppression. Carboplatin is active against squamous cell carcinoma of cervix and appears to be less nephrotoxic, neurotoxic, and nauseogenic than cisplatin. Randomized studies of this drug against cisplatin are indicated to determine the role of carboplatin in the therapy of squamous cell carcinoma of cervix.

Original languageEnglish
Pages (from-to)187-191
Number of pages5
JournalInvestigational New Drugs
Volume4
Issue number2
DOIs
StatePublished - Jun 1986

Fingerprint

Carboplatin
Cervix Uteri
Squamous Cell Carcinoma
Cisplatin
Therapeutics
Pharmaceutical Preparations
Radiotherapy
Bone Marrow

Keywords

  • carboplatin
  • cervix
  • Phase II
  • squamous cell carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

A Phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study). / Arseneau, James; Blessing, John A.; Stehman, Frederick; McGehee, Ramon.

In: Investigational New Drugs, Vol. 4, No. 2, 06.1986, p. 187-191.

Research output: Contribution to journalArticle

@article{5d66817b21b949d385f0f0db5b0b0dcd,
title = "A Phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study)",
abstract = "The Gynecologic Oncology Group conducted a Phase II trial of carboplatin in patients with measurable advanced squamous cell carcinoma of cervix. No prior therapy with cytotoxic drugs was permitted in patients entered into this study. Patients entered were GOG performance status 2 or better. Carboplatin 400 mg/m2 (340 mg/m2 in patients who had had prior pelvic radiotherapy with subsequent escalation to 400 mg/m2 if bone marrow tolerance was good) was administered as a 15-minute IV infusion. Treatments were repeated every four weeks until disease progressed or until toxicity prohibited further therapy. Thirty-nine evaluable patients were treated. Two complete and nine partial responses were observed (response rate 28.2{\%}). No neurotoxicity and only mild reversible nephrotoxicity was seen. Gastrointestinal toxicity was severe in three patients (7.7{\%}). Dose limiting toxicity was myelosuppression. Carboplatin is active against squamous cell carcinoma of cervix and appears to be less nephrotoxic, neurotoxic, and nauseogenic than cisplatin. Randomized studies of this drug against cisplatin are indicated to determine the role of carboplatin in the therapy of squamous cell carcinoma of cervix.",
keywords = "carboplatin, cervix, Phase II, squamous cell carcinoma",
author = "James Arseneau and Blessing, {John A.} and Frederick Stehman and Ramon McGehee",
year = "1986",
month = "6",
doi = "10.1007/BF00194601",
language = "English",
volume = "4",
pages = "187--191",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A Phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study)

AU - Arseneau, James

AU - Blessing, John A.

AU - Stehman, Frederick

AU - McGehee, Ramon

PY - 1986/6

Y1 - 1986/6

N2 - The Gynecologic Oncology Group conducted a Phase II trial of carboplatin in patients with measurable advanced squamous cell carcinoma of cervix. No prior therapy with cytotoxic drugs was permitted in patients entered into this study. Patients entered were GOG performance status 2 or better. Carboplatin 400 mg/m2 (340 mg/m2 in patients who had had prior pelvic radiotherapy with subsequent escalation to 400 mg/m2 if bone marrow tolerance was good) was administered as a 15-minute IV infusion. Treatments were repeated every four weeks until disease progressed or until toxicity prohibited further therapy. Thirty-nine evaluable patients were treated. Two complete and nine partial responses were observed (response rate 28.2%). No neurotoxicity and only mild reversible nephrotoxicity was seen. Gastrointestinal toxicity was severe in three patients (7.7%). Dose limiting toxicity was myelosuppression. Carboplatin is active against squamous cell carcinoma of cervix and appears to be less nephrotoxic, neurotoxic, and nauseogenic than cisplatin. Randomized studies of this drug against cisplatin are indicated to determine the role of carboplatin in the therapy of squamous cell carcinoma of cervix.

AB - The Gynecologic Oncology Group conducted a Phase II trial of carboplatin in patients with measurable advanced squamous cell carcinoma of cervix. No prior therapy with cytotoxic drugs was permitted in patients entered into this study. Patients entered were GOG performance status 2 or better. Carboplatin 400 mg/m2 (340 mg/m2 in patients who had had prior pelvic radiotherapy with subsequent escalation to 400 mg/m2 if bone marrow tolerance was good) was administered as a 15-minute IV infusion. Treatments were repeated every four weeks until disease progressed or until toxicity prohibited further therapy. Thirty-nine evaluable patients were treated. Two complete and nine partial responses were observed (response rate 28.2%). No neurotoxicity and only mild reversible nephrotoxicity was seen. Gastrointestinal toxicity was severe in three patients (7.7%). Dose limiting toxicity was myelosuppression. Carboplatin is active against squamous cell carcinoma of cervix and appears to be less nephrotoxic, neurotoxic, and nauseogenic than cisplatin. Randomized studies of this drug against cisplatin are indicated to determine the role of carboplatin in the therapy of squamous cell carcinoma of cervix.

KW - carboplatin

KW - cervix

KW - Phase II

KW - squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0022482045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022482045&partnerID=8YFLogxK

U2 - 10.1007/BF00194601

DO - 10.1007/BF00194601

M3 - Article

C2 - 3525449

AN - SCOPUS:0022482045

VL - 4

SP - 187

EP - 191

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -